Seinda develops a point-of-care diagnosis platform for ophthalmic diagnosis and treatment.
Seinda develops a point-of-care diagnosis platform for ophthalmic diagnosis and treatment. Seinda is committed to establishing an open ophthalmic omics platform, conducting molecular mechanism research on eye diseases, developing innovative diagnosis and treatment products, meeting clinical needs, gaining market premium, and building a world-class Chinese brand.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 23, 2020 | Seed | — | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Xie Yao Capital | — | Seed |
Zhuhai Qirong Venture Capital Management | — | Seed |